logo
  

Dycom Industries Q4 Results Top Estimates - Quick Facts

While reporting financial results for the third quarter on Tuesday, specialty contracting services firm Dycom Industries, Inc. (DY) said it anticipates contract revenues for the first quarter to increase mid-to-high single digits as a percentage from last year.

On average, eight analysts polled by Thomson Reuters expect the company to report earnings of $3.28 per share on revenues of $3.38 billion for the year. Analysts' estimates typically exclude special items.

For the fourth quarter, net income was $0.794 million or $0.03 per share, compared to a net loss of $4.20 million or $0.13 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter was $0.02 per share, compared to an adjusted loss of $0.07 per share in the year-ago quarter.

Contract revenues for the quarter grew to $761.48 million from $750.67 million in the same quarter last year.

Contract revenues increased 10.1 percent on an organic basis after excluding contract revenues from storm restoration services and adjusting for the additional week.

The Street was looking for a loss of $0.03 per share on revenues of $722.32 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
RELATED NEWS
Follow RTT